Red blood cells and the vasculature.

Acceleron’s ACE-031 protein therapeutic for DMD receives FDA Fast Track designation Acceleron Pharma, Inc medication information ., a biopharmaceutical organization developing novel therapeutics that modulate the development of tissues and cells including muscles, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy , a fatal neuromuscular disease where patients have problems with the progressive loss of muscle strength and mass. ACE-031 is an investigational protein therapeutic getting developed to improve muscle strength and mass. We will work collaboratively with medical investigators, health authorities and individual advocacy groups around the global world to develop ACE-031.